Hikma Proves Resilient In 2020 Despite Some Bumpy Launches

Rivals To Advair And Vascepa Suffer From Delays And API Scarcity

 
• By Dave Wallace

Despite turbulence in 2020 from the coronavirus pandemic as well as from difficulties relating to two of its key US generic launches, Hikma has reported solid full-year growth in both sales and profits across its business.

Plane Aeroplane Turbulence Clouds Flight
Hikma has come through turbulence in 2020 to report solid growth • Source: Shutterstock

More from Earnings

More from Business